BioSpace News Archive

Ivy Brain Tumor Center at Barrow Neurological Institute announced today that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations.

KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the United States Patent and Trademark Office (USPTO) has recently issued two (2) new patents to KemPharm governing methods of use and composition of matter for methylphenidate-based prodrugs.

HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for HST5040, a once-daily oral small molecule drug being developed to treat methylmalonic acidemia (MMA) and propionic acidemia (PA).

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020 . The press release will be followed by a conference call at 8:00

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2020 financial results after market close on Tuesday, August 4 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to discuss

Recordati Rare Diseases Inc. announces today that Lancet Diabetes & Endocrinology has published results from the Phase III LINC-3 pivotal study of ISTURISA, recently approved for the treatment of Cushing’s disease in adults

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the U.S. Patent and Trademark Office issued U.S. Pat. No. 10,723,763, titled, Use of Tight Junction Antagonists in the Treatment of Acute Lung

Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, announced today that Pedro Lichtinger, Chairman and Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium Pres

Micron Medical, a privately-held medical device company engaged in the development, manufacture and pre-commercialization of innovative wireless, minimally invasive, electroceutical solutions for urological conditions, today announced the appointment of Nick Ansari as Senior Vice President of Sales. Mr. Ansari has an impressive track record of success with more than 25 years of experience in field sales and commercialization in the medical de

Nu-Med Plus, Inc., a medical device company which investigates and develops applications and devices for nitric oxide delivery in the medical field, announced that the United States Patent and Trademark Office has issued US patent #10682486 for a single-use or short-term use nitric oxide inhaler.